Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NSCA-1
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
NSCA-1 is a novel N-substituted coumalamide derivative, belonging to the 2-pyrone class of compounds. It has been investigated for its potential to overcome multidrug resistance in hepatocellular carcinoma, specifically by sensitizing HepG2/ADR cells to the chemotherapeutic agent Adriamycin (doxorubicin). The drug's mechanism of action involves the inhibition of Akt kinase activity and the reduction of Akt phosphorylation at Ser473, which leads to decreased phosphorylation of GSK-3β. Additionally, NSCA-1 has been shown to boost the intracellular accumulation of Adriamycin by reducing the expression of P-glycoprotein (P-gp) and to enhance cell apoptosis through the p53-dependent apoptotic pathway.
- Other names
- N-substituted coumalamide derivative-1
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)TP53 (Cellular Tumor Antigen p53 R175H)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on NSCA-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NSCA-1.